文献速递肝胆胰外科围术期管理与 ERAS

胰十二指肠切除术后切缘状态对导管腺癌预后的价值:法国前瞻性多中心研究更新

Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
PubMed 文献 · Ann Surg · 2017-01-01

该前瞻性多中心研究纳入147例胰头导管腺癌患者,采用标准化病理方案评估肿瘤清除度。结果显示R0率随R1定义从0mm改为<1.0mm由75%降至35%,pN是最强独立预测因子(P=0.004),清除度<1.0或<1.5mm在特定亚组中为独立预后因素。

要点

  • R1定义从0mm改为<1.0mm时R0率由75%降至35%。
  • pN是5年生存最强独立预测因子(P=0.004)。
  • 清除度<1.0或<1.5mm在特定亚组中与生存独立相关。

核心结论

  • 肿瘤清除度<1.0或<1.5mm是特定亚组术后生存的独立决定因素。
  • 未来试验应明确以毫米为单位规定清除切缘。

研究设计与样本

  • 前瞻性多中心研究,纳入147例胰头导管腺癌患者,采用标准化病理方案评估肿瘤清除度。
  • 住院死亡率为3%(5/147),随访83个月。

主要发现

  • 肿瘤清除度为0、<1.0、<1.5和<2.0mm的患者分别有35例(25%)、92例(65%)、95例(67%)和109例(77%)。
  • R1定义从直接侵犯(0mm)改为<1.0mm时,R0率从75%降至35%。
  • 单因素分析中,清除度<1.0或<1.5mm、pT分期、pN分期、LNR≥0.2、肿瘤分级3级和淋巴血管侵犯与5年生存显著相关。
  • 多因素分析中pN是最强独立预测因子(P=0.004)。
  • 清除度<1.0或<1.5mm在全队列中为临界显著性,但在特定亚组中相关: upfront胰切除(n=117;P=0.049)、无静脉切除或新辅助治疗(n=87;P=0.003)、N+且无静脉切除或新辅助治疗(n=50;P=0.004)。

关键数值与推荐

  • R1定义从0mm改为<1.0mm时R0率由75%降至35%。
  • pN为最强独立预测因子(P=0.004)。
  • 清除度<1.0或<1.5mm在upfront胰切除亚组P=0.049、无静脉切除或新辅助治疗亚组P=0.003、N+且无静脉切除或新辅助治疗亚组P=0.004。
  • 新辅助治疗组后切缘R1-0mm的P=0.004。

临床怎么用

  • 病理报告应明确切缘清除度的毫米数值,避免R1定义歧义。
  • 对upfront胰切除、无静脉切除或新辅助治疗、N+且无静脉切除或新辅助治疗等亚组,应关注清除度<1.0或<1.5mm的预后意义。
  • 新辅助治疗患者需关注后切缘R1-0mm的独立风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to assess the relevance of resection margin status for survival after resection of pancreatic-head ductal adenocarcinoma. SUMMARY BACKGROUND DATA: The definition and prognostic value of incomplete microscopic resection (R1) remain controversial. METHODS: Prognostic factors were analyzed in 147 patients included in a prospective multicenter study on the impact of tumor clearance evaluated using a standardized pathology protocol. RESULTS: Thirty patients received neoadjuvant treatment (NAT = 20%); 41 had venous resection (VR = 28%), and 70% received adjuvant chemotherapy. In-hospital mortality was 3% (5/147). Follow-up was 83 months. Tumor clearance was 0, <1.0, <1.5, and <2.0 mm in 35 (25%), 92 (65%), 95 (67%), and 109 (77%) patients, respectively. R0-resection rates decreased from 75% to 35% when changing the definition of R1 status from R1-direct invasion (0 mm) to R1 <1.0 mm. On univariate analysis, clearance <1.0 or <1.5 mm, pT stage, pN stage, LNR ≥0.2, tumor grade 3, and lymphovascular invasion were significantly associated with 5-year survival. On multivariate analysis, pN was the most powerful independent predictor (P = 0.004). Clearance <1.0 or <1.5 mm had borderline significance for the entire cohort, but was relevant in certain subgroups (upfront pancreatectomy (n = 117; P = 0.049); without VR or NAT (n = 87; P = 0.003); N+ without VR or NAT (n = 50; P = 0.004). No N0-patient had R1-0 mm. Additional independent risk predictors were (1) R1 <1.0 mm for the SMA-margin in specific subgroups (upfront pancreatectomy, N0 patients without NAT, N+ patients without NAT or VR; (2) R1-0 mm posterior-margin for the NAT group (P = 0.004). CONCLUSION: Tumor clearance <1.0 or <1.5 mm was an independent determinants of postresection survival in certain subgroups. To avoid misinterpretation, future trials should specify the clearance margin in millimeter. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00918853.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Delpero JR, Jeune F, Bachellier P, et al. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Ann Surg. 2017. PMID: 28953554. doi:10.1097/SLA.0000000000002432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。